Increased human intestinal barrier permeability plasma biomarkers zonulin and FABP2 correlated with plasma LPS and altered gut microbiome in anxiety or depression

Zonulin is the master regulator of endothelial and epithelium tight junctions, modulating both gut and blood-brain barriers. 3 We analysed stool faecal microbiota and plasma in 50 subjects who self-reported to be asymptomatic for gastrointestinal physical disorders; 22 volunteers met Diagnostic and...

Full description

Saved in:
Bibliographic Details
Published inGut Vol. 67; no. 8; pp. 1555 - 1557
Main Authors Stevens, Bruce R, Goel, Ruby, Seungbum, Kim, Richards, Elaine M, Holbert, Richard C, Pepine, Carl J, Raizada, Mohan K
Format Journal Article
LanguageEnglish
Published England BMJ Publishing Group LTD 01.08.2018
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Zonulin is the master regulator of endothelial and epithelium tight junctions, modulating both gut and blood-brain barriers. 3 We analysed stool faecal microbiota and plasma in 50 subjects who self-reported to be asymptomatic for gastrointestinal physical disorders; 22 volunteers met Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria for a depressive disorder or an anxiety disorder (DEP/ANX), and 28 more were control reference subjects (NODEPANX). Figure 2; Plasma LPS endotoxin, zonulin and fatty acid-binding protein-2 (FABP2) blood markers of gut dysbiosis and gut permeability pathophysiological epithelium integrity. 3 4 Analysis of variance yielded significant mean differences (p<0.05) (see online supplementary material ). Funding: University of Florida Clinical and Translational Science Institute grant (BRS, CJP) from the National Center For Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR001427; National Institute of Health (NIH) grants HL33610, HL56921 (MKR, CJP); UM1 HL087366 (CJP); Gatorade Trust through funds distributed by the University of Florida, Department of Medicine (CJP); PCORI-OneFlorida Clinical Research Consortium CDRN-1501-26692 (CJP); and internal funds from the University of Florida Department of Physiology and Functional Genomics (BRS, MKR).
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Commentary-3
content type line 23
ISSN:0017-5749
1468-3288
1468-3288
DOI:10.1136/gutjnl-2017-314759